PUMA mediates the anti-cancer effect of osimertinib in colon cancer cells

Osimertinib, an irreversible EGFR/HER2 inhibitor, has been found to be effective in the cancer cell with EGFR gene mutations in preclinical lung cancer models. However, the effect of osimertinib in colorectal cancer (CRC) cells is unclear. In the present study, we investigated how osimertinib suppre...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Lingchuan, Huang, Shan, Wang, Xinwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680964/
https://www.ncbi.nlm.nih.gov/pubmed/29138581
http://dx.doi.org/10.2147/OTT.S139382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680964/
https://www.ncbi.nlm.nih.gov/pubmed/29138581
http://dx.doi.org/10.2147/OTT.S139382

Ejemplares similares